

Please add the following new claims 15-34:

Sub C1
~~15. A method of treating Type I diabetes mellitus in a mammal comprising administering to said mammal an effective amount of an insulin and an effective amount of a glucagon-like peptide 1 (7-36) amide agonist, wherein said glucagon-like peptide 1 (7-36) amide agonist is administered orally.~~

~~16. A method according to claim ¹~~15~~ wherein said mammal is a human.~~

Sub C2
~~17. A method according to claim 16 wherein said insulin and said glucagon-like peptide 1 (7-36) amide agonist are administered to the human at a selected time prior to ingestion of a meal.~~

~~18. A method according to any of claims 15-17 wherein said glucagon-like peptide 1 (7-36) amide agonist is glucagon-like peptide 1 (7-36).~~

~~19. A method according to any of claims 15-17 wherein said glucagon-like peptide 1 (7-36) amide agonist is glucagon-like peptide 1 (7-36) amide.~~

~~20. A method of treating Type I diabetes mellitus in a mammal comprising administering an effective amount of a glucagon-like peptide 1 (7-36) amide agonist, wherein said glucagon-like peptide 1 (7-36) amide agonist is administered orally.~~

2

6

21. A method according to claim 20 wherein said mammal is a human.

Sub

22. A method according to claim 21 wherein said glucagon-like peptide 1 (7-36) amide agonist is administered to the human at a selected time prior to ingestion of a meal.

23. A method according to any of claims 20-22 wherein said glucagon-like peptide 1 (7-36) amide agonist is glucagon-like peptide 1 (7-36).

24. A method according to any of claims 20-22 wherein said glucagon-like peptide 1 (7-36) amide agonist is glucagon-like peptide 1 (7-36) amide.

25. A method of treating Type I diabetes mellitus in a mammal comprising administering to said mammal an effective amount of an insulin and an effective amount of a glucagon-like peptide 1 (7-36) amide agonist, wherein said glucagon-like peptide 1 (7-36) amide agonist is administered nasally.

26. A method according to claim 25 wherein said mammal is a human.

Sub

27. A method according to claim 26 wherein said insulin and said glucagon-like peptide 1 (7-36) amide agonist are administered to the human at a selected time prior to ingestion of a meal.

~~28. A method according to any of claims 25-27 wherein said glucagon-like peptide 1 (7-36) amide agonist is glucagon-like peptide 1 (7-36).~~

~~29. A method according to any of claims 25-27 wherein said glucagon-like peptide 1 (7-36) amide agonist is glucagon-like peptide 1 (7-36) amide.~~

~~30. A method of treating Type 1 diabetes mellitus in a mammal comprising administering an effective amount of a glucagon-like peptide 1 (7-36) amide agonist, wherein said glucagon-like peptide 1 (7-36) amide agonist is administered nasally.~~

~~31. A method according to claim 30 wherein said mammal is a human.~~

~~32. A method according to claim 31 wherein said glucagon-like peptide 1 (7-36) amide agonist is administered to the human at a selected time prior to ingestion of a meal.~~

~~33. A method according to any of claims 30-32 wherein said glucagon-like peptide 1 (7-36) amide agonist is glucagon-like peptide 1 (7-36).~~

~~34. A method according to any of claims 30-32 wherein said glucagon-like peptide 1 (7-36) amide agonist is glucagon-like peptide 1 (7-36) amide.~~